Ultragenyx price target lowered to $61 from $71 at Goldman Sachs

Goldman Sachs lowered the firm’s price target on Ultragenyx (RARE) to $61 from $71 and keeps a Buy rating on the shares. Ultragenyx reported 4Q revenue of $207M, above prior consensus, driven by Crysvita and Dojolvi and provided FY26 revenue guidance of $730M-$760M excluding potential new launches, the analyst tells investors in a research note. Management is focused on cost reductions to maintain a path to 2027 profitability and upcoming clinical catalysts, including Phase 3 GTX-102 data in Angelman syndrome, as well as gene therapy programs UX701, DTX401, and UX111, which will shape the company’s pipeline execution and strategic outlook, the firm says.